Janux Therapeutics (JANX) Return on Capital Employed: 2021-2025
Historic Return on Capital Employed for Janux Therapeutics (JANX) over the last 4 years, with Sep 2025 value amounting to -0.14%.
- Janux Therapeutics' Return on Capital Employed fell 2.00% to -0.14% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.14%, marking a year-over-year decrease of 2.00%. This contributed to the annual value of -0.14% for FY2024, which is 6.00% up from last year.
- Latest data reveals that Janux Therapeutics reported Return on Capital Employed of -0.14% as of Q3 2025, which was down 1.53% from -0.14% recorded in Q2 2025.
- In the past 5 years, Janux Therapeutics' Return on Capital Employed ranged from a high of -0.06% in Q3 2021 and a low of -0.23% during Q2 2023.
- Over the past 3 years, Janux Therapeutics' median Return on Capital Employed value was -0.14% (recorded in 2025), while the average stood at -0.16%.
- Its Return on Capital Employed has fluctuated over the past 5 years, first declined by 12bps in 2022, then increased by 14bps in 2024.
- Over the past 5 years, Janux Therapeutics' Return on Capital Employed (Quarterly) stood at -0.09% in 2021, then declined by 10bps to -0.19% in 2022, then decreased by 1bps to -0.20% in 2023, then increased by 8bps to -0.11% in 2024, then declined by 2bps to -0.14% in 2025.
- Its Return on Capital Employed stands at -0.14% for Q3 2025, versus -0.14% for Q2 2025 and -0.11% for Q1 2025.